The efficacy of pivmecillinam for empirical treatment of acute uncomplicated urinary tract infection (UTI) was initially reported in clinical trials published in the 1970s and 1980s. Bacteriological cure rates observed in these trials were consistently >85%, and studies of different dosing regimens suggested that a 3 day course was appropriate. Comparative studies reported that pivmecillinam was equivalent to other antimicrobial agents in terms of clinical and bacteriological outcomes. These studies also documented that pivmecillinam was effective for treatment of Staphylococcus saprophyticus infections, was acceptable for use in pregnancy and was well tolerated. Subsequent widespread use of pivmecillinam in Scandinavian countries has led to a body of clinical experience which confirms the efficacy and safety of this antimicrobial agent in the treatment of acute cystitis. Recently, two large, prospective, randomized, double-blind, multi-centre clinical trials have been completed to assist in defining the role of this antimicrobial agent in the treatment of acute cystitis. A comparison of 3 day courses of pivmecillinam or norfloxacin, both at 400 mg bd, showed higher bacteriological cure rates with norfloxacin but generally similar clinical outcomes. A second, dose-ranging study found that pivmecillinam, given bd for 7 days, led to superior bacteriological and clinical outcomes at short-term follow-up than the 3 day regimen. Pooling bacteriological outcomes from the two studies showed similar outcomes with 7 days of pivmecillinam 200 mg bd or 3 days of norfloxacin 400 mg bd. The shorter, 3 day, course achieved similar short-term clinical outcomes to 7 days of pivmecillinam and 3 days of norfloxacin in women aged 50 years. These recent studies confirm earlier reports and clinical experience that pivmecillinam is effective and well tolerated for the treatment of acute cystitis in women. <
Introduction
Acute uncomplicated urinary tract infection (UTI) is a common clinical problem in women. 1 Antimicrobial management for this problem has evolved over several decades, as susceptibility of Escherichia coli isolates in the community to available therapies has changed and new antimicrobial agents have been introduced. 2 Pivmecillinam was introduced approximately 20 years ago as an option for the treatment of acute uncomplicated UTI. It has been used in the treatment of acute cystitis for many years, but use has been limited to relatively few countries, primarily in Scandinavia. The Swedish Board of Health recommends pivmecillinam as a first-choice option for the treatment of acute cystitis. 3 Between 20% and 30% of prescriptions for acute cystitis in Denmark, Sweden and Norway are for pivmecillinam. In Finland, 10% of episodes of acute cystitis are treated with pivmecillinam. 4 With this widespread use, no problems in efficacy or concerns about adverse effects have been identified, and clinically significant resistance to pivmecillinam has not developed in community E. coli isolates. 2 Given the increasing problem of resistance with first-line agents such as co-trimoxazole or quinolones, more widespread use of pivmecillinam could be considered. This paper reviews current evidence supporting the use of pivmecillinam for treatment of acute cystitis, including initial results from two recently completed clinical trials. trials which evaluated different dosing regimens.
5-13 Doses of pivmecillinam ranged from 200 mg tds to 400 mg bd or tds, with durations of therapy of 3, 5, 7 or 10 days. All regimens had bacteriological cure rates approaching or exceeding 90%. Clinical outcomes, where reported, were consistent with bacteriological outcomes. Table II summarizes the results of comparative clinical trials. [13] [14] [15] [16] [17] [18] [19] Pivmecillinam was generally equivalent to the comparator agent, although bacteriological outcome was significantly superior to nalidixic acid in one study. 16 
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Staphylococcus saprophyticus
Staphylococcus saprophyticus is the second most frequent bacterium isolated in acute cystitis, but generally comprises Ͻ10% of isolates.
1 Any empirical treatment of acute cystitis must be effective for this organism. Mecillinam is not effective against Gram-positive cocci; its in vitro MIC for S. saprophyticus is 8-64 mg/L, 16 so these bacteria are considered resistant. Several studies have specifically reviewed outcomes with S. saprophyticus infection. Cure rates of 73%, 20 89% 16 and 92% 10 have been reported. The success of therapy probably reflects the very high urinary concentrations of pivmecillinam (Ͼ200 mg/L) achieved by antimicrobial excretion into the urine. 21 The outcome of treating S. saprophyticus infection with pivmecillinam is comparable to that reported for other antimicrobial agents, so pivmecillinam is effective empirical therapy for this infection.
Use in pregnancy
Several studies have reported the safety and efficacy of pivmecillinam in pregnancy. Bacteriological cure rates for the treatment of asymptomatic bacteriuria in pregnant women of 90%, 22 88% 23 and 87% 24 have been observed. There has been no evidence of an adverse effect on the pregnancy or the fetus with pivmecillinam therapy in these studies. There has also been substantial clinical experience using pivmecillinam for acute cystitis in pregnant women. In particular, in Finland, pivmecillinam is the third most commonly prescribed antibiotic in pregnancy and the most frequently used for urinary infection in pregnancy. 25 No adverse effects have been recognized with this extensive clinical experience over many years. Thus pivmecillinam is an effective therapy for management of acute cystitis or asymptomatic bacteriuria in pregnancy.
Adverse effects
The most common complaints reported with pivmecillinam therapy are mild gastrointestinal symptoms such as nausea. 2 Other adverse effects reported include rash and vulvovaginitis, which occur at a frequency no greater than with other -lactam antibiotics. In clinical trials, adverse effects reported with pivmecillinam have generally been identified in Ͻ10% of subjects, a proportion similar to that with comparator antimicrobial agents. Therapy has rarely had to be discontinued because of adverse effects. Thus, the safety profile of pivmecillinam is acceptable.
Recent clinical trials
Pivmecillinam compared with norfloxacin
Since the introduction and initial evaluation of pivmecillinam, quinolone antimicrobial agents have been marketed and are now widely used for treatment of UTIs. A recent large, prospective, multicentre, randomized, double-blind trial was undertaken to compare the efficacy of pivmecillinam 400 mg bd with norfloxacin 400 mg bd, each for 3 days. Telephone follow-up to document clinical response was done 4 days after the start of therapy. At early (11 days after the start of therapy) and late (39 days after the start of therapy) follow-up, urine specimens were taken to assess bacteriological outcome and subjects were interviewed to assess clinical response. Subjects enrolled included 483 women randomized to pivmecillinam and 471 to norfloxacin, with mean ages of 38.5 and 38.1 years, respectively. A positive pretherapy urine culture was obtained for 330 (68%) of those who received pivmecillinam and 334 (71%) of those who received norfloxacin. Organisms isolated were those anticipated for acute uncomplicated UTI, and included E. coli (80%), S. saprophyticus (3.6%), Proteus mirabilis (5.2%) and Enterococcus faecalis (4.3%). Of these isolates, 90% were susceptible to pivmecillinam and 99% to norfloxacin (99% of E. coli were susceptible to pivmecillinam).
At the early post-therapy follow-up, the bacteriological cure rate was 75% for pivmecillinam and 91% for norfloxacin (P Ͻ 0.001). There was a significant variation in outcome among different countries, however; the range for bacteriological cure in individual countries was 65-100% for pivmecillinam and 75-100% for norfloxacin. There was no clear explanation for this variation among countries. After 4 days there was a satisfactory clinical response for 95% of subjects who had received pivmecillinam and 96% who had received norfloxacin (95% CI, -2.0% to 10.8%). After 11 days, 82% and 88% of subjects receiving pivmecillin and and norfloxacin, respectively, had achieved clinical cure (95% CI, 0.9% to 10.3%). Adverse events occurred with equal frequency in the two study arms; four subjects discontinued pivmecillinam and ten norfloxacin because of adverse events.
Bacteriological response did not correlate with the pretherapy antimicrobial susceptibility of the organism. For subjects randomized to receive pivmecillinam, 79% of subjects with susceptible organisms, 81% of those with intermediately susceptible organisms and 88% of those with resistant organisms were judged to be cured at early follow-up. The high cure rate with resistant organisms is primarily a result of the effectiveness of pivmecillinam in infections with Gram-positive cocci. The clinical cure rate with pivmecillinam varied with age, with 84% of women Ͻ50 years successfully treated and only 77% of those Ͼ50 years. For norfloxacin, no age variation was observed and 88% of women were judged to be clinically cured at the early follow-up.
Dose-ranging study
A second recent clinical trial was a dose-ranging study which also included a placebo arm. In this study, pivmecil-linam 200 mg tds for 7 days, 200 mg bd for 7 days and 400 mg bd for 3 days were compared with placebo. A total of 1162 women, with a mean age of 43.1 years, were recruited in 18 Swedish centres. Of the 796 (69%) bacteriologically evaluable patients, 8-10 days after therapy, cure rates were 85% and 90% in the bd and tds 7 day regimens, respectively, 79% in the 3 day regimen and 28% in the placebo group. All three pivmecillinam regimens were superior to placebo. The 7 day bd regimen was significantly better than the 3 day regimen (P ϭ 0.002) but the 7 day tds regimen showed only a trend to improved outcome (P ϭ 0.068). The clinical responses also showed a trend to improved response with 7 days of therapy compared with 3 days of therapy. At the early post-treatment visit, 74% of women in either of the 7 day regimens had a positive clinical response, compared with 68% in the 3 day regimen and only 43% in the placebo group. The frequency of adverse effects was similar for all four groups.
Optimal pivmecillinam regimen
Pooling of data from the two studies provides insight into the efficacy of the different dosing regimens of pivmecillinam compared with norfloxacin (Table III) . Pooling was felt to be acceptable for bacteriological outcome because the entry criteria and characteristics of patients enrolled were similar and the bacteriological outcome criteria were consistent. To correct for multiple comparisons between different regimens, the Bonferroni correction was used. The short-term bacteriological outcome was similar for pivmecillinam 200 mg bd for 7 days and norfloxacin 400 mg bd for 3 days. If only women of р50 years are considered, both 7 day pivmecillinam regimens were equivalent to norfloxacin (Table III) . Data were not pooled for clinical outcome because the two studies used different methods. However, the data from the two studies separately show that, in women of р50 years of age, at short-term followup, the 3 day pivmecillinam regimen was equivalent to either 7 day regimen in the first study and to norfloxacin in the second study (Table IV) .
Discussion
Pivmecillinam is suitable for the treatment of acute uncomplicated UTI. Evaluation in clinical trials and clinical experience has shown it to be effective and safe. A 7 day regimen gives better outcomes than a 3 day course, consistent with observations with other -lactam antimicrobial agents used to treat acute cystitis. Clinical response, however, may be better than bacteriological response. The 7 day bd dosing regimen has equivalent bacteriological outcome to norfloxacin given for 3 days. Current guidelines for treating acute uncomplicated cystitis recommend empirical therapy without pre-and post-therapy urine cultures. 26 The shorter 3 day course of pivmecillinam would be effective empirical therapy for the majority of women, particularly premenopausal women. Thus, pivmecillinam is an appropriate agent for use in empirical therapy of acute uncomplicated UTI. Use of pivmecillinam may spare the use of other agents, such as co-trimoxazole and quinolone antimicrobial agents, where there are concerns about resistance emerging in community E. coli and it may be desirable to preserve these other agents for treatment of infections other than acute cystitis. a CI, -12.5% to -0.7% (P ϭ 0.027) and -9.9% to ϩ3.5% (P ϭ 0.35) versus norfloxacin.
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b CI, -7.2% to ϩ3.5% (P ϭ 0.51) and -3.7% to ϩ7.8% (P ϭ 0.48) versus norfloxacin. c CI, -19.9% to -10.1% (P Ͻ 0.001) and -17.9% to -6.9% (P Ͻ 0.001) versus norfloxacin. Using the Bonferroni correction for multiple comparisons, P Ͻ 0.008 is considered significant; two-tailed. (84) a CI, ϩ15.6% to ϩ35.0% (P Ͻ 0.001) and ϩ12.1% to ϩ42.4% (P Ͻ 0.001) versus placebo. b CI, ϩ1.6% to -14.3% (P ϭ 0.06) and -10.2% to ϩ10.9% (P ϭ 0.93) versus 200 mg bd 7 days. c CI, ϩ2.1% to -14.0% (P ϭ 0.08) and -11.6% to ϩ9.4% (P ϭ 0.81) versus 200 mg tds 7 days. d CI, 0.7% to 10.0% (P ϭ 0.02) and -1.3% to 9.1% (P ϭ 0.141) versus norfloxacin. Using the Bonferroni correction for multiple comparisons, P Ͻ 0.017 is considered significant.
